These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33888515)

  • 1. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
    Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
    Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
    Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
    Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
    Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
    J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
    Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
    Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in Colorectal Cancer Screening from the National Health Interview Survey: Analysis of the Impact of Different Modalities on Overall Screening Rates.
    Ebner DW; Finney Rutten LJ; Miller-Wilson LA; Markwat N; Vahdat V; Ozbay AB; Limburg PJ
    Cancer Prev Res (Phila); 2024 Jun; 17(6):275-280. PubMed ID: 38561018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
    Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
    Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
    Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
    Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy.
    Bonello B; Ghanouni A; Bowyer HL; MacRae E; Atkin W; Halloran SP; Wardle J; von Wagner C
    BMC Gastroenterol; 2016 Sep; 16(1):113. PubMed ID: 27618798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment.
    Heidenreich S; Finney Rutten LJ; Miller-Wilson LA; Jimenez-Moreno C; Chua GN; Fisher DA
    Cancer Med; 2022 Aug; 11(16):3156-3167. PubMed ID: 35315224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
    Pickhardt PJ; Correale L; Hassan C
    AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
    Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.